Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash from Investing Activities: 2021-2025

Historic Cash from Investing Activities for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to -$4.3 million.

  • Krystal Biotech's Cash from Investing Activities rose 87.51% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$153.4 million, marking a year-over-year decrease of 70.74%. This contributed to the annual value of -$163.4 million for FY2024, which is 297.78% down from last year.
  • Krystal Biotech's Cash from Investing Activities amounted to -$4.3 million in Q3 2025, which was up 59.28% from -$10.5 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Cash from Investing Activities ranged from a high of $105.2 million in Q3 2023 and a low of -$126.5 million during Q4 2021.
  • In the last 3 years, Krystal Biotech's Cash from Investing Activities had a median value of -$16.0 million in 2023 and averaged -$13.7 million.
  • As far as peak fluctuations go, Krystal Biotech's Cash from Investing Activities slumped by 7,384.34% in 2022, and later skyrocketed by 813.50% in 2023.
  • Krystal Biotech's Cash from Investing Activities (Quarterly) stood at -$126.5 million in 2021, then soared by 95.88% to -$5.2 million in 2022, then plummeted by 95.08% to -$10.2 million in 2023, then slumped by 724.59% to -$83.8 million in 2024, then spiked by 87.51% to -$4.3 million in 2025.
  • Its Cash from Investing Activities was -$4.3 million in Q3 2025, compared to -$10.5 million in Q2 2025 and -$54.8 million in Q1 2025.